Maxcyte (MXCT) Enterprise Value (2021 - 2026)

Maxcyte (MXCT) has reported Enterprise Value for 6 consecutive years, with $24.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value fell 76.51% year-over-year to $24.9 million in Q2 2026; TTM through Jun 2026 was $24.9 million, a 76.51% decrease from a year earlier, with the FY2025 full-year figure at $62.5 million, down 78.1% from the prior year.
• Enterprise Value was $24.9 million for Q2 2026 at Maxcyte, up from -$31.6 million in the prior quarter.
• Over five years, Enterprise Value peaked at $463.3 million in Q1 2022 and troughed at -$31.6 million in Q1 2026.
• A 5-year average of $217.3 million and a median of $254.7 million in 2024 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value surged 92.56% in 2024 and plunged 120.79% in 2026, its largest moves.
• Over 5 years, Enterprise Value stood at $331.8 million in 2022, then fell by 3.44% to $320.3 million in 2023, then declined by 10.94% to $285.3 million in 2024, then plunged by 78.1% to $62.5 million in 2025, then sank by 60.22% to $24.9 million in 2026.
• The last three Enterprise Value figures came in at $24.9 million (Q2 2026), -$31.6 million (Q1 2026), and $62.5 million (Q4 2025), per Business Quant data.